Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911)

The Lancet

Volumn 380, Issue 9858, 2012, Pages 2018-2027

  Bolla, Michel ^a   Van Poppel, Hein ^b   Tombal, Bertrand ^c   Vekemans, Kris ^d   Da Pozzo, Luigi ^e   De Reijke, Theo M ^c   Verbaeys, Antony ^g   Bosset, Jean François ^h   Van Velthoven, Roland ⁱ   Colombel, Marc ^j   Van De Beek, Cees ^k   Verhagen, Paul ^l   Van Den Bergh, Alphonsus ^m   Sternberg, Cora ⁿ   Gasser, Thomas ^o   Van Tienhoven, Geertjan ^f   Scalliet, Pierre ^c   Haustermans, Karin ^b   Collette, Laurence ^p  

^a HÔPITAL MICHALLON   (France)

^b Katholieke Universiteit   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d VIRGA JESSE HOSPITAL   (Belgium)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^o UNIVERSITY HOSPITAL BASEL   (Switzerland)

^p EORTC DATA CENTER   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL;

EID: 84870485783     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61253-7     Document Type: Article

References (28)

1. National Institutes of Health Consensus Development Panel. Consensus statement: the management of clinically localized prostate cancer. NCI Monogr 1988; 7: 3-6.
2. Epstein JL, Carmichael M, Partin AW, et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinoma of the prostate with 5-year follow-up. J Urol 1993; 149: 1478-93.
3. Myers RP, Fleming TR. Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 1983; 4: 461-69.
4. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043-52.
5. Collette L, van Poppel H, Bolla M, et al. Patients at risk of progression after radical prostatectomy: do they all benefi t from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 2005; 41: 2662-72.
6. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-78.
7. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate specifi c antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30.
8. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized trial. JAMA 2006; 296: 2329-35.
9. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer signifi cantly reduces risk of metastases and improves survival: long term follow-up of a randomized trial. J Urol 2009; 181: 956-62.
10. Spiessl B, Beahrs OH, Hermanek P, et al, eds. TNM atlas: illustrated guide to the TNM/pTNM-classifi cation of malignant tumors, 3rd edn. Berlin: Springer-Verlag, 1989.
11. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
12. International Commission on Radiation Units and Measurements. ICRU Report 29. Dose specifi cation for reporting external beam therapy with photons and electrons. Washington, DC: International Commission on Radiation Units and Measurements, 1978.
13. Davis B, Reiner B, Dusserre A, Giraud JY, Bolla M. Quality assurance of the EORTC trial 22911. A phase III study of post-operative external irradiation radiotherapy in pathological stage T3N0 prostatic carcinoma: the dummy-run. Radiother Oncol 2002; 64: 65-73.
14. Kalbfl eisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980: 163-78.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
16. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15.
17. Morgan SC, Waldron TS, Eapen L, et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008; 88: 1-9.
18. Parker C, Sydes MR, Catton C, et al, for the RADICALS Trial Management Group. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007; 99: 1376-79.
19. Trabulsi EJ, Valicenti RK, Hanlon AL, et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N03. Urology 2008; 72: 1298-302.
20. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specifi c survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008; 299: 2760-69.
21. Cookson MS, Aus G, Burnett AL, et al. Variation in the defi nition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-45.
22. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-41.
23. King CR. Adjuvant radiotherapy after prostatectomy: does waiting for a prostate specifi c antigen level make sense? Int J Radiat Oncol Biol Phys 2011; 80: 1-3.
24. Yossepowitch O, Bjartell A, Eastham JA, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009; 55: 87-99.
25. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identifi cation of patients with prostate cancer who benefi t from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-86.
26. Poortmans P, Bossi A, Vandeputte K, et al. Guidelines for target volume defi nition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007; 84: 121-27.
27. Ost P, Fonteyne V, Villeirs G, Lumen N, Oosterlinck W, De Meerleer G. Adjuvant high dose-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 2009; 56: 669-77.
28. Shipley WU, Hunt D, Lukka HR, et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels. 2011 Genitourinary Cancer Symposium; Orlando, FL; Feb 17-19, 2011.